Back to Search
Start Over
MLN4924 therapy as a novel approach in cancer treatment modalities.
- Source :
-
Journal of chemotherapy (Florence, Italy) [J Chemother] 2016 Apr; Vol. 28 (2), pp. 74-82. - Publication Year :
- 2016
-
Abstract
- MLN4924 is an investigational and a newly discovered small molecule that is a potent and selective inhibitor of the NEDD8 (Neural precursor cell-Expressed Developmentally down-regulated 8) Activating Enzyme (NAE), a pivotal regulator of the Cullin Ring Ligases E3 (CRL), which has been implicated recently in DNA damage. MLN4924 effectively inhibits tumour cell growth by inducing all three common types of death, namely apoptosis, autophagy and senescence and it was also reported that the formation of capillary vessels was significantly suppressed by MLN4924.In this review, we are going to highlight the molecular mechanism of MLN4924 in cancer therapy and its pros and cons in cancer therapy.
- Subjects :
- Antineoplastic Agents pharmacology
Apoptosis
Autophagy
Cell Cycle Proteins metabolism
Cullin Proteins antagonists & inhibitors
Cyclopentanes pharmacology
Humans
NF-KappaB Inhibitor alpha metabolism
Neoplasms drug therapy
Neoplasms metabolism
Neoplasms pathology
Neoplasms radiotherapy
Proto-Oncogene Proteins c-bcl-2 metabolism
Pyrimidines pharmacology
Radiation-Sensitizing Agents therapeutic use
Antineoplastic Agents therapeutic use
Cyclopentanes therapeutic use
Pyrimidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1973-9478
- Volume :
- 28
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of chemotherapy (Florence, Italy)
- Publication Type :
- Academic Journal
- Accession number :
- 26292710
- Full Text :
- https://doi.org/10.1179/1973947815Y.0000000066